search
Back to results

Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels

Primary Purpose

Psoriasis Vulgaris, Psoriatic Arthritis, Metabolic Syndrome

Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
omentin, visfatin
Sponsored by
Istanbul Medeniyet University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Psoriasis Vulgaris focused on measuring psoriasis vulgaris, psoriatic arthritis, metabolic syndrome, omentin, visfatin

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Patients followed up for psoriasis and psoriatic arthritis in dermatology and rheumatology clinic
  2. Patients older than 18 years
  3. Patients who accept dermatological and rheumatic examination
  4. Patients not receiving systemic treatment related to the disease in the last 1 month

Exclusion Criteria:

  1. Patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis
  2. Patients under 18 years
  3. Patients who do not accept dermatological and rheumatic examination Patients receiving systemic therapy for the last 1 month pregnant and nursing moms

Sites / Locations

  • Istanbul Medeniyet University, Department of dermatology
  • Istanbul Medeniyet University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Other

Other

Arm Label

psoriasis vulgaris,

psoriatic arthritis

healthy control

Arm Description

patients who have only psoriasis vulgaris

patients who have psoriatic arthritis

healthy people

Outcomes

Primary Outcome Measures

omentin
Omentin (omentin 1-2) is a specific protein that consists of amino acids released from vascular vessels
visfatin
Visfatin is an insulin-like protein that binds to insulin receptors produced mostly from visceral fatty tissue.

Secondary Outcome Measures

Full Information

First Posted
April 24, 2019
Last Updated
June 14, 2019
Sponsor
Istanbul Medeniyet University
search

1. Study Identification

Unique Protocol Identification Number
NCT03932110
Brief Title
Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels
Official Title
The Prevalence of Metabolic Syndrome in Patients With Psoriasis and Psoriatic Arthritis and Its Correlation With Disease Severity and Serum Omentin-1 and Visfatin Levels
Study Type
Interventional

2. Study Status

Record Verification Date
June 2019
Overall Recruitment Status
Completed
Study Start Date
April 15, 2019 (Actual)
Primary Completion Date
June 1, 2019 (Actual)
Study Completion Date
June 14, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Istanbul Medeniyet University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
In this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis patients as well as the parameters of metabolic syndrome will be examined. At the same time, the levels of omentin and visfatin adipokines associated with metabolic syndrome and obesity will be measured by measuring the disease severity (by PASI psoriasis, clinical activity score for psoriatic arthritis). The patients who accepted to participate in the study , who were admitted to the dermatology outpatient clinic were included in the study. For the blood tests required after the examination, 2 tubes of blood will be taken for the measurement of omentin and visfatin. 80 psoriasis, 40 psoriatic arthritis and 60 healthy volunteers were planned to be studied. AHA / NHLBI, 2005 (revised ATP III criteria) criterion for the diagnosis of metabolic syndrome will be used. Omentin and visfatin levels are compared with the severity of the disease for psoriasis and psoriatic arthritis, and it will be examined whether it is proinflammatory or antiinflammatory.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psoriasis Vulgaris, Psoriatic Arthritis, Metabolic Syndrome
Keywords
psoriasis vulgaris, psoriatic arthritis, metabolic syndrome, omentin, visfatin

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
180 (Actual)

8. Arms, Groups, and Interventions

Arm Title
psoriasis vulgaris,
Arm Type
Other
Arm Description
patients who have only psoriasis vulgaris
Arm Title
psoriatic arthritis
Arm Type
Other
Arm Description
patients who have psoriatic arthritis
Arm Title
healthy control
Arm Type
Other
Arm Description
healthy people
Intervention Type
Diagnostic Test
Intervention Name(s)
omentin, visfatin
Intervention Description
diagnostic blood test
Primary Outcome Measure Information:
Title
omentin
Description
Omentin (omentin 1-2) is a specific protein that consists of amino acids released from vascular vessels
Time Frame
6 months
Title
visfatin
Description
Visfatin is an insulin-like protein that binds to insulin receptors produced mostly from visceral fatty tissue.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients followed up for psoriasis and psoriatic arthritis in dermatology and rheumatology clinic Patients older than 18 years Patients who accept dermatological and rheumatic examination Patients not receiving systemic treatment related to the disease in the last 1 month Exclusion Criteria: Patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis Patients under 18 years Patients who do not accept dermatological and rheumatic examination Patients receiving systemic therapy for the last 1 month pregnant and nursing moms
Facility Information:
Facility Name
Istanbul Medeniyet University, Department of dermatology
City
Istanbul
ZIP/Postal Code
34722
Country
Turkey
Facility Name
Istanbul Medeniyet University
City
Istanbul
ZIP/Postal Code
34722
Country
Turkey

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels

We'll reach out to this number within 24 hrs